Seaport Therapeutics SPTX Unrealized gains (losses) on available-for-sale securities

Unrealized gains (losses) on available-for-sale securities at other companies

TFS FinancialTFSL

-$1.91M-136%

Rhythm Pharmaceuticals, Inc.RYTM

-$544K-5,340%

Jackson FinancialJXN

-$552M-191%

Procore TechnologiesPCOR

-$474K-700%

Flagstar Bank FLG

-$39M-142%

PopularBPOP

$12.24M-93.1%

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Market cap$972.65M—

Enterprise value$925.08M—

Debt / equity-0×—

Current ratio13.2×—

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Seaport Therapeutics 's unrealized gains (losses) on available-for-sale securities?: Seaport Therapeutics (SPTX) reported unrealized gains (losses) on available-for-sale securities of -$252K in Q1 2026.